More than 90% of thyroid cancers are DTC, which originate from thyroid follicular epithelial cells and include mainly papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), with a few Hǔrthle cell or eosinophilic tumors. Most DTCs progress slowly and have a nearly benign course with a high 10-year survival rate, but certain histologic subtypes (hypercellular type of PTC, columnar cell type, diffuse sclerosing type, solid subtype and extensive infiltrative type of FTC, etc.) of DTC are prone to extrathyroidal invasion, vascular invasion and distant metastasis, with high recurrence rate and relatively poor prognosis. Hypofractionated thyroid cancer also belongs to the category of DTC. These tumors are relatively rare and have insular, beam-like, or solid structures, but do not have the typical nuclear features of PTC and have at least one of the following three morphological features: nuclear distortion, nuclear schizophrenia ≥ 3/10 high magnification field, and necrosis. The clinico-biological characteristics of this type of tumor are highly aggressive, prone to metastasis and poor prognosis, which is one of the difficulties in the current treatment of DTC. The treatment methods of DTC mainly include: surgical treatment, postoperative 131I treatment and TSH suppression treatment. The overall trend of DTC treatment is individualized and comprehensive treatment.